

Special Issue

Vaccine Efficacy and Disease Burden Evaluation

Message from the Guest Editor

Vaccines represent one of the most significant public health interventions for the prevention of infectious diseases. However, their success relies on rigorous evaluations of vaccine efficacy and effectiveness (VE), as well as accurate assessments of disease burden. VE varies by population, context, and pathogen mutations, while disease burden—encompassing incidence, mortality, and economic and societal impacts—guides vaccine prioritization and resource allocation. We are pleased to invite you to contribute to this Special Issue, entitled “Evaluation of Vaccine Efficacy and Disease Burden”. This Special Issue aims to collate high-quality research that advances methodologies and provides insights into VE evaluation and disease burden estimation. For this Special Issue, original research articles and reviews are welcome to be submitted. Topics of interest include, but are not limited to, the following: research on vaccine efficacy, effectiveness, and safety across populations; studies on immunity persistence and correlates of protection; quantification of disease burden for vaccine-preventable diseases; impact assessments of vaccination programs; and methodological innovations.

Guest Editor

Dr. Xiaoli Wang

Beijing Center for Disease Prevention and Control, School of Public Health, Capital Medical University, Beijing, China

Deadline for manuscript submissions

31 August 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/251515

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).